TESARO Inc (TSRO) Position Decreased by Spark Investment Management LLC

Spark Investment Management LLC lessened its holdings in TESARO Inc (NASDAQ:TSRO) by 29.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 57,600 shares of the biopharmaceutical company’s stock after selling 24,100 shares during the period. Spark Investment Management LLC owned about 0.11% of TESARO worth $3,291,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also made changes to their positions in the company. BlackRock Inc. increased its stake in TESARO by 5.6% during the 4th quarter. BlackRock Inc. now owns 4,067,066 shares of the biopharmaceutical company’s stock worth $337,039,000 after buying an additional 213,920 shares in the last quarter. BB Biotech AG increased its stake in TESARO by 55.8% during the 1st quarter. BB Biotech AG now owns 1,629,743 shares of the biopharmaceutical company’s stock worth $93,124,000 after buying an additional 583,550 shares in the last quarter. TimesSquare Capital Management LLC increased its stake in TESARO by 226.1% during the 4th quarter. TimesSquare Capital Management LLC now owns 856,600 shares of the biopharmaceutical company’s stock worth $70,986,000 after buying an additional 593,924 shares in the last quarter. Rock Springs Capital Management LP increased its stake in TESARO by 10.8% during the 4th quarter. Rock Springs Capital Management LP now owns 548,500 shares of the biopharmaceutical company’s stock worth $45,454,000 after buying an additional 53,250 shares in the last quarter. Finally, Alliancebernstein L.P. increased its stake in TESARO by 16.9% during the 4th quarter. Alliancebernstein L.P. now owns 513,542 shares of the biopharmaceutical company’s stock worth $42,557,000 after buying an additional 74,290 shares in the last quarter.

In related news, SVP Orlando Oliveira sold 3,000 shares of the company’s stock in a transaction that occurred on Thursday, March 8th. The stock was sold at an average price of $69.88, for a total value of $209,640.00. Following the transaction, the senior vice president now directly owns 9,076 shares in the company, valued at $634,230.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Grant C. Bogle sold 1,809 shares of the company’s stock in a transaction that occurred on Thursday, March 1st. The shares were sold at an average price of $54.85, for a total value of $99,223.65. The disclosure for this sale can be found here. Over the last quarter, insiders purchased 334,913 shares of company stock worth $19,083,294 and sold 13,042 shares worth $760,526. Corporate insiders own 33.70% of the company’s stock.

Several research firms have commented on TSRO. Citigroup cut their price objective on TESARO from $102.00 to $100.00 and set a “buy” rating for the company in a research note on Friday, May 4th. BidaskClub upgraded TESARO from a “strong sell” rating to a “sell” rating in a research note on Tuesday, March 6th. Credit Suisse Group cut their price objective on TESARO from $141.00 to $128.00 and set an “outperform” rating for the company in a research note on Friday, May 4th. Bank of America cut their price objective on TESARO from $94.00 to $88.00 and set a “buy” rating for the company in a research note on Friday, May 4th. Finally, Lake Street Capital reiterated a “buy” rating and set a $80.00 price objective (down from $120.00) on shares of TESARO in a research note on Monday, May 7th. One analyst has rated the stock with a sell rating, ten have issued a hold rating and fifteen have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $119.00.

TSRO stock opened at $51.76 on Friday. The company has a debt-to-equity ratio of 3.74, a current ratio of 4.02 and a quick ratio of 3.56. TESARO Inc has a 1 year low of $44.76 and a 1 year high of $168.92.

TESARO (NASDAQ:TSRO) last posted its quarterly earnings results on Thursday, May 3rd. The biopharmaceutical company reported ($2.98) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.56) by ($0.42). TESARO had a negative net margin of 193.42% and a negative return on equity of 177.92%. The company had revenue of $49.74 million during the quarter, compared to analysts’ expectations of $56.34 million. During the same quarter last year, the company earned ($2.55) earnings per share. TESARO’s revenue for the quarter was up 1520.2% on a year-over-year basis. equities analysts anticipate that TESARO Inc will post -9.96 EPS for the current year.

TESARO Profile

Tesaro, Inc, an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It offers ZEJULA (niraparib), an orally active and potent poly polymerase inhibitor for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and VARUBI (rolapitant), a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting.

Want to see what other hedge funds are holding TSRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TESARO Inc (NASDAQ:TSRO).

Institutional Ownership by Quarter for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply